Tirzepatide Improves Body Composition and Muscle Function in Obese Patients

Obesity is a complex, chronic metabolic disease associated with numerous health complications, including cardiovascular disease, type 2 diabetes, and impaired physical function. While novel dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists like Tirzepatide have demonstrated remarkable efficacy for weight loss in clinical trials, less is known about their specific impact on body composition changes and muscle function in real-world clinical settings. This study aimed to evaluate Tirzepatide's effects on lean mass, fat mass, and physical performance in a diverse patient population receiving standard care.

Patients treated with Tirzepatide demonstrated significant and clinically meaningful improvements across multiple metabolic and functional parameters. The cohort experienced an average total body weight reduction of 18.5% (p<0.001) from baseline over the 24 weeks. > The most impactful finding was a substantial 22.1% reduction in total fat mass, coupled with a remarkable 3.8% preservation of lean muscle mass, indicating a highly favorable shift in body composition. Beyond weight and fat loss, muscle function also improved significantly, with average grip strength increasing by 12.5% (p<0.01) and the distance covered in the 6-minute walk test extending by 15.2% (p<0.001) compared to baseline. These comprehensive changes suggest that Tirzepatide not only promotes significant weight loss but also fosters a healthier body composition and enhances physical capability.